EUR J CANCER 2020 10.1016/j.ejca.2020.03.029
Outstanding clinical efficacy of PD-1/PD-L1 inhibitors for pulmonary pleomorphic carcinoma
Lee1, J; La Choi, Y; Jung, HA; Lee, SH; Ahn, JS; Ahn, MJ; Park, K; Sun, JM

NAT COMMUN 2020 10.1038/s41467-020-16164-1
Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma
Kim1, N; Kim, HK; Lee, K; Hong, Y; Cho, JH; Choi, JW; Lee, J; Suh, YL; Ku, BM; Eum, HH; Choi, S; Choi, YL; Joung, JG; Park, WY; Jung, HA; Sun, JM; Lee, SN; Ahn, JS; Park, K; Ahn, MJ; Lee, HO

CLIN LUNG CANCER 2020 10.1016/j.cllc.2019.11.006
Benefit of Targeted DNA Sequencing in Advanced Non-Small-Cell Lung Cancer Patients Without EGFR and ALK Alterations on Conventional Tests
Byeon1, S; Lee, B; Park, WY; Choi, YL; Jung, HA; Sun, JM; Ahn, JS; Ahn, MJ; Park, K; Lee, SH

J MOL DIAGN 2020 10.1016/j.jmoldx.2019.10.015
Junction Location Identifier (JuLI) Accurate Detection of DNA Fusions in Clinical Sequencing for Precision Oncology
Shin1, HT; Kim, NKD; Yun, JW; Lee, B; Kyung, S; Lee, KW; Ryu, D; Kim, J; Bae, JS; Park, D; Choi, YL; Lee, SH; Ahn, MJ; Park, K; Park, WY

MOL THER-ONCOLYTICS 2020 10.1016/j.omto.2019.12.009
IRS2 Amplification as a Predictive Biomarker in Response to Ceritinib in Small Cell Lung Cancer
Lee1, MS; Jung, K; Song, JY; Sung, MJ; Ahn, SB; Lee, B; Oh, DY; Choi, YL

BIOMOLECULES 2020 10.3390/biom10010051
Development of Human Monoclonal Antibody for Claudin-3 Overexpressing Carcinoma Targeting
Yang1, H; Park, H; Lee, YJ; Choi, JY; Kim, T; Rajasekaran, N; Lee, S; Song, K; Hong, S; Choi, JS; Shim, H; Kim, YD; Hwang, S; Choi, YL; Shin, YK

Front Oncol 2020 10.3389/fonc.2019.01574
UBE2C Overexpression Aggravates Patient Outcome by Promoting Estrogen-Dependent/Independent Cell Proliferation in Early Hormone Receptor-Positive and HER2-Negative Breast Cancer
Kim1, YJ; Lee, GH; Han, JN; Song, K; Choi, JS; Choi, YL; Shin, YK

BREAST CANCER RES 2019 10.1186/s13058-019-1197-x
High expression of NR1D1 is associated with good prognosis in triple-negative breast cancer patients treated with chemotherapy
Na1, H; Han, J; Ka, NL; Lee, MH; Choi, YL; Shin, YK; Lee, MO

J CLIN MED 2019 10.3390/ijms20194794
Association with PD-L1 Expression and Clinicopathological Features in 1000 Lung Cancers: A Large Single-Institution Study of Surgically Resected Lung Cancers with a High Prevalence of EGFR Mutation
Lee1, SE; Kim, YJ; Sung, M; Lee, MS; Han, J; Kim, HK; Choi, YL

J MOL MED-JMM 2019 10.1007/s00109-019-01815-8
Molecular changes in solitary fibrous tumor progression
Park1, HK; Yu, DB; Sung, MJ; Oh, E; Kim, M; Song, JY; Lee, MS; Jung, K; Noh, KW; An, S; Song, K; Nam, DH; Kim, YJ; Choi, YL

J GASTROEN HEPATOL 2019 10.1111/jgh.14915
Nomogram for prediction of lymph node metastasis in patients with superficial esophageal squamous cell carcinoma
Min1, BH; Yang, JW; Min, YW; Baek, SY; Kim, S; Kim, HK; Choi, YS; Shim, YM; Choi, YL; Zo, JI

EUR RADIOL 2019 10.1007/s00330-019-06445-9
Soft tissue sarcoma: DWI and DCE-MRI parameters correlate with Ki-67 labeling index
Lee1, JH; Yoon, YC; Seo, SW; Choi, YL; Kim, HS

EUR J CANCER 2019 10.1016/j.ejca.2019.08.001
Genomic scoring to determine clinical benefit of immunotherapy by targeted sequencing
Kim1, HS; Cha, H; Kim, JH; Park, WY; Choi, YL; Sun, JM; Ahn, JS; Ahn, MJ; Park, K; Lee, SH

J PLAST RECONSTR AES 2019 10.1016/j.bjps.2019.05.021
Capsule biopsy of acellular dermal matrix (ADM) to predict future capsular contracture in two-stage prosthetic breast reconstruction
Kim1, A; Jung, JH; Choi, YL; Pyon, JK

LAB INVEST 2019 10.1038/s41374-019-0263-4
Co-expression of MDM2 and CDK4 in transformed human mesenchymal stem cells causes high-grade sarcoma with a dedifferentiated liposarcoma-like morphology
Kim1, YJ; Kim, M; Park, HK; Yu, DB; Jung, K; Song, K; Choi, YL

J CLIN ONCOL 2019 10.1200/JCO.2017.77.3184
Pembrolizumab for Patients With Refractory or Relapsed Thymic Epithelial Tumor: An Open-Label Phase II Trial
Cho1, J; Kim, HS; Ku, BM; Choi, YL; Cristescu, R; Han, J; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

CANCER SCI 2019 10.1111/cas.14036
Adipogenesis induces growth inhibition of dedifferentiated liposarcoma
Kim1, YJ; Yu, DB; Kim, M; Choi, YL

LUNG CANCER 2019 10.1016/j.lungcan.2019.05.024
Paired genomic analysis of squamous cell carcinoma transformed from EGFR-mutated lung adenocarcinoma
Park1, S; Shim, JH; Lee, B; Cho, I; Park, WY; Kim, Y; Lee, SH; Choi, YL; Han, J; Ahn, JS; Ahn, MJ; Park, K; Sun, JM

Front Oncol 2019 10.3389/fonc.2019.00667
Comparison of GenesWell BCT Score With Oncotype DX Recurrence Score for Risk Classification in Asian Women With Hormone Receptor-Positive, HER2-Negative Early Breast Cancer
Kwon1, MJ; Lee, JE; Jeong, J; Woo, SU; Han, J; Kang, BI; Kim, JE; Moon, Y; Lee, SB; Lee, S; Choi, YL; Kwon, Y; Song, K; Gong, G; Shin, YK

PATHOL RES PRACT 2019 10.1016/j.prp.2019.152441
Histopathologic characteristics of advanced-stage ROS1-rearranged non-small-cell lung cancers
Park1, E; Choi, YL; Ahn, MJ; Han, J

MOL ONCOL 2019 10.1002/1878-0261.12478
Identification of tumor suppressor miRNAs by integrative miRNA and mRNA sequencing of matched tumor-normal samples in lung adenocarcinoma
Yu1, N; Yong, S; Kim, HK; Choi, YL; Jung, Y; Kim, D; Seo, J; Lee, YE; Baek, D; Lee, J; Lee, S; Lee, JE; Kim, J; Kim, J; Lee, S

J IMMUNOTHER CANCER 2019 10.1186/s40425-019-0609-x
Paired whole exome and transcriptome analyses for the Immunogenomic changes during concurrent chemoradiotherapy in esophageal squamous cell carcinoma
Park1, S; Joung, JG; Min, YW; Nam, JY; Ryu, D; Oh, D; Park, WY; Lee, SH; Choi, YL; Ahn, JS; Ahn, MJ; Park, K; Sun, JM

CLIN LUNG CANCER 2019 10.1016/j.cllc.2018.12.021
Transthoracic Rebiopsy for Mutation Analysis in Lung Adenocarcinoma: Outcomes and Risk Factors for the Acquisition of Nondiagnostic Specimens in 199 Patients
Da Nam1, B; Kim, TJ; Park, K; Ahn, MJ; Choi, YL; Chung, MJ; Kim, TS; Lee, KS

CLIN LUNG CANCER 2019 10.1016/j.cllc.2018.12.020
Efficacy and Safety of Lorlatinib in Korean Non-Small-Cell Lung Cancer Patients With ALK or ROS1 Rearrangement Whose Disease Failed to Respond to a Previous Tyrosine Kinase Inhibitor
Lee1, J; Sun, JM; Lee, SH; Ahn, JS; Park, K; Choi, YL; Ahn, MJ

BMC CANCER 2019 10.1186/s12885-019-5713-2
Combination therapy with c-met inhibitor and TRAIL enhances apoptosis in dedifferentiated liposarcoma patient-derived cells
Jo1, EB; Lee, YS; Lee, H; Park, JB; Park, H; Choi, YL; Hong, D; Kim, SJ

CANCER RES TREAT 2019 10.4143/crt.2018.151
Clinical Outcomes of EGFR Exon 20 Insertion Mutations in Advanced Non-small Cell Lung Cancer in Korea
Byeon1, S; Kim, Y; Lim, SW; Cho, JH; Park, S; Lee, J; Sun, JM; Choi, YL; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

CANCER RES TREAT 2019 10.4143/crt.2018.125
EGFR Mutation Is Associated with Short Progression-Free Survival in Patients with Stage III Non-squamous Cell Lung Cancer Treated with Concurrent Chemoradiotherapy
Park1, SE; Noh, JM; Kim, YJ; Lee, HS; Cho, JH; Lim, SW; Ahn, YC; Pyo, H; Choi, YL; Han, J; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

LUNG CANCER 2019 10.1016/j.lungcan.2019.01.012
Repeat biopsy procedures and T790M rates after afatinib, gefitinib, or erlotinib therapy in patients with lung cancer
Lee1, K; Kim, Y; Jung, HA; Lee, SH; Ahn, JS; Ahn, MJ; Park, K; Choi, YL; Sun, JM

J THORAC ONCOL 2019 10.1016/j.jtho.2018.10.150
Concurrent Genetic Alterations Predict the Progression to Target Therapy in EGFR-Mutated Advanced NSCLC
Kim1, Y; Lee, B; Shim, JH; Lee, SH; Park, WY; Choi, YL; Sun, JM; Ahn, JS; Ahn, MJ; Park, K
외 다수